Sponsor

R-Pharm

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name R-Pharm appears in 25 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials25
Recruiting shown0
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

25 shown
A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With ExacerbationsNCT07597668 · lead sponsor · 2025-04-16
ACTIVE_NOT_RECRUITING
A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast CancerNCT07386938 · lead sponsor · 2024-08-09
ACTIVE_NOT_RECRUITING
Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant NeoplasmsNCT06307093 · lead sponsor · 2023-03-01
COMPLETED
A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral DrugsNCT03537404 · lead sponsor · 2017-04-24
COMPLETED
Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial HypertensionNCT02248961 · lead sponsor · 2014-05-01
COMPLETED
Phase I Combination Ixabepilone + CisplatinNCT00832117 · lead sponsor · 2009-05-01
COMPLETED
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung CancerNCT00723957 · lead sponsor · 2008-12-01
COMPLETED
Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung CancerNCT00683904 · lead sponsor · 2008-06-01
COMPLETED
Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast CancerNCT00633464 · lead sponsor · 2008-06-01
COMPLETED
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerNCT00634088 · lead sponsor · 2008-06-01
TERMINATED
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast CancerNCT00593827 · lead sponsor · 2008-05-01
COMPLETED
Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast CancerNCT00546364 · lead sponsor · 2008-02-01
TERMINATED
A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast CancerNCT00568022 · lead sponsor · 2008-02-01
COMPLETED
A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast CancerNCT00490646 · lead sponsor · 2008-02-01
COMPLETED
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast CancerNCT00370552 · lead sponsor · 2007-03-01
COMPLETED
A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An AnthracyclineNCT01027208 · lead sponsor · 2006-12-01
COMPLETED
Phase I Combination w/ EpirubicinNCT00322374 · lead sponsor · 2006-08-01
COMPLETED
Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane ResistantNCT01019577 · lead sponsor · 2005-10-01
COMPLETED
Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)NCT00080262 · lead sponsor · 2004-02-01
COMPLETED
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast CancerNCT00082433 · lead sponsor · 2003-11-01
COMPLETED
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast CancerNCT00080301 · lead sponsor · 2003-09-01
COMPLETED
BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast CancerNCT00049244 · lead sponsor · 2002-09-01
UNKNOWN
A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based ChemotherapyNCT00035516 · lead sponsor · 2001-02-01
COMPLETED
The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid ArthritisNCT01533714 · collaborator · 2012-01-26
TERMINATED
Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056NCT01296711 · collaborator · 2011-03-07
TERMINATED

Drugs studied in this sponsor's trials

10 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing R-Pharm as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
ixabepilone10
capecitabine4
docetaxel2
trastuzumab2
cisplatin1
epirubicin1
losartan1
raltegravir1
ixabepilone RxCUI 337523 · Lead sponsor in 10 linked trial(s) · 0 currently recruiting 10 trials capecitabine RxCUI 194000 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials docetaxel RxCUI 72962 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials trastuzumab RxCUI 224905 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials cisplatin RxCUI 2555 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial epirubicin RxCUI 3995 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial losartan RxCUI 52175 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial raltegravir RxCUI 719872 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial ritonavir RxCUI 85762 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial tenofovir disoproxil fumarate RxCUI 322248 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor23
collaborator2
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.